{"id":"rifampicin-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Orange-red discoloration of body fluids"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Drug interactions (enzyme induction)"}]},"_chembl":{"chemblId":"CHEMBL374478","moleculeType":"Small molecule","molecularWeight":"822.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifampicin binds to the bacterial RNA polymerase enzyme and inhibits RNA synthesis by blocking the path of the elongating RNA transcript. This mechanism is highly selective for bacterial RNA polymerase and has minimal effect on eukaryotic RNA polymerases, making it effective as an antibiotic. It is bactericidal and works against a broad spectrum of gram-positive and gram-negative bacteria, as well as mycobacteria.","oneSentence":"Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:59.725Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (pulmonary and extrapulmonary)"},{"name":"Leprosy"},{"name":"Atypical mycobacterial infections"},{"name":"Prophylaxis of meningococcal meningitis"},{"name":"Brucellosis"}]},"trialDetails":[{"nctId":"NCT06192160","phase":"PHASE2","title":"Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-11","conditions":"Pulmonary Tuberculosis","enrollment":315},{"nctId":"NCT07374224","phase":"PHASE1","title":"A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2026-03-05","conditions":"Clinical Pharmacology","enrollment":28},{"nctId":"NCT06889701","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants","status":"RECRUITING","sponsor":"TenNor Therapeutics Inc.","startDate":"2025-04-03","conditions":"Periprosthetic Joint Infection (PJI)","enrollment":33},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT07429331","phase":"PHASE1","title":"Drug Interaction and Food Effect Study of CS0159","status":"NOT_YET_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2026-03","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT03012529","phase":"PHASE4","title":"Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-01-22","conditions":"Osteomyelitis, Diabetes, Amputation","enrollment":843},{"nctId":"NCT07330531","phase":"PHASE4","title":"Drug-drug Interaction Study of Rifampin and Anaprazole Sodium","status":"NOT_YET_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2026-01-04","conditions":"Drug-drug Interaction Study","enrollment":24},{"nctId":"NCT07134478","phase":"PHASE1","title":"Clinical Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of HSK31858 in Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2024-10-28","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT04630145","phase":"PHASE2, PHASE3","title":"A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-01-08","conditions":"Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","enrollment":129},{"nctId":"NCT04606537","phase":"PHASE1","title":"Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects","status":"COMPLETED","sponsor":"KBP Biosciences","startDate":"2020-10-24","conditions":"Healthy, Drug Drug Interaction","enrollment":24},{"nctId":"NCT06024915","phase":"PHASE1","title":"A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-09-21","conditions":"Myelofibrosis","enrollment":40},{"nctId":"NCT07014488","phase":"PHASE1","title":"A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-06-20","conditions":"Prostate Cancer","enrollment":16},{"nctId":"NCT07002255","phase":"PHASE1","title":"A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rifampicin Capsules (RIF)","status":"COMPLETED","sponsor":"Henan Genuine Biotech Co., Ltd.","startDate":"2021-12-20","conditions":"Healthy","enrollment":15},{"nctId":"NCT05057949","phase":"PHASE1","title":"A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-11-24","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT02846519","phase":"PHASE1","title":"Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-02-26","conditions":"Healthy","enrollment":66},{"nctId":"NCT05577624","phase":"PHASE1","title":"A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-11-05","conditions":"Healthy Participants","enrollment":14},{"nctId":"NCT05388448","phase":"PHASE2","title":"EBA, Safety and Tolerability of Sanfetrinem Cilexetil","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2022-04-21","conditions":"Tuberculosis, Pulmonary","enrollment":54},{"nctId":"NCT06822166","phase":"PHASE1","title":"Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-12-04","conditions":"Interaction Drug Food","enrollment":68},{"nctId":"NCT06701136","phase":"PHASE1","title":"Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiatan Pharmatech Co., Ltd","startDate":"2025-05-12","conditions":"Rifampicin-Resistant Pulmonary Tuberculosis Patients","enrollment":16},{"nctId":"NCT02729467","phase":"PHASE1","title":"A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-03","conditions":"Healthy","enrollment":33},{"nctId":"NCT06255951","phase":"PHASE1","title":"Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"TYK Medicines, Inc","startDate":"2024-03-12","conditions":"NSCLC","enrollment":48},{"nctId":"NCT06619951","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2024-09-18","conditions":"Locally Advanced or Metastatic Solid Tumor","enrollment":56},{"nctId":"NCT05899829","phase":"PHASE1","title":"Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2023-06-21","conditions":"Cough, Healthy","enrollment":42},{"nctId":"NCT06662773","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) Study for TQB3616","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11","conditions":"Healthy","enrollment":40},{"nctId":"NCT06089733","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021","status":"COMPLETED","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2023-04-11","conditions":"Healthy Subjects","enrollment":32},{"nctId":"NCT03782662","phase":"PHASE1","title":"A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-11-07","conditions":"Respiratory Syncytial Virus Infections","enrollment":82},{"nctId":"NCT06031454","phase":"PHASE1","title":"Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-09-01","conditions":"Drug Drug Interaction","enrollment":56},{"nctId":"NCT06344936","phase":"PHASE1","title":"Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2024-04","conditions":"Chronic Kidney Disease(CKD)","enrollment":28},{"nctId":"NCT06332053","phase":"PHASE1","title":"A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2024-04-01","conditions":"Healthy Subjects","enrollment":28},{"nctId":"NCT05635110","phase":"PHASE1","title":"Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-12-15","conditions":"Pain","enrollment":31},{"nctId":"NCT06246695","phase":"PHASE1","title":"A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2021-10-27","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT06165822","phase":"PHASE1","title":"A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-12","conditions":"Advanced Malignant Neoplasm","enrollment":40},{"nctId":"NCT05685719","phase":"PHASE1","title":"A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558","status":"COMPLETED","sponsor":"Zhejiang ACEA Pharmaceutical Co. Ltd.","startDate":"2023-01-04","conditions":"COVID-19 Pneumonia","enrollment":37},{"nctId":"NCT05098041","phase":"PHASE1","title":"A Study of Soticlestat and Rifampin in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-11-22","conditions":"Healthy Volunteers","enrollment":15},{"nctId":"NCT05826574","phase":"PHASE1","title":"A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2023-05-10","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT04830462","phase":"PHASE4","title":"Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation","status":"COMPLETED","sponsor":"Herlev and Gentofte Hospital","startDate":"2021-04-15","conditions":"Latent Tuberculosis, Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT01323465","phase":"PHASE1","title":"Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2008-02","conditions":"Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor","enrollment":36},{"nctId":"NCT04532918","phase":"PHASE1","title":"Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-09-10","conditions":"Chronic Kidney Disease","enrollment":14},{"nctId":"NCT03982277","phase":"PHASE2","title":"Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy","status":"COMPLETED","sponsor":"Makerere University","startDate":"2019-04-30","conditions":"Tuberculosis","enrollment":130},{"nctId":"NCT05497674","phase":"PHASE1","title":"Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2022-02-21","conditions":"Type 2 Diabetes Mellitus","enrollment":28},{"nctId":"NCT05720767","phase":"PHASE1","title":"HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2022-11-04","conditions":"Relapsed or Refractory Lymphoma","enrollment":28},{"nctId":"NCT04933682","phase":"PHASE1","title":"Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-06-23","conditions":"Healthy","enrollment":16},{"nctId":"NCT05631678","phase":"PHASE1","title":"Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole","status":"COMPLETED","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","startDate":"2022-06-06","conditions":"Locally Advanced or Metastatic NSCLC","enrollment":48},{"nctId":"NCT05586568","phase":"PHASE1","title":"Drug-drug Interaction Study of XZP-3621 Tablet","status":"UNKNOWN","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-11-15","conditions":"Healthy Subjects","enrollment":72},{"nctId":"NCT05316857","phase":"PHASE1","title":"DDI Study of Orelabrutinib","status":"COMPLETED","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2021-12-16","conditions":"Healthy Person","enrollment":36},{"nctId":"NCT04907019","phase":"PHASE1","title":"A Drug Interaction Study of SY-004 Capsules in Healthy Subjects","status":"COMPLETED","sponsor":"Suzhou Yabao Pharmaceutical R&D Co., Ltd.","startDate":"2021-07-06","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT03063580","phase":"PHASE1","title":"Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-02-27","conditions":"Diabetes Mellitus","enrollment":16},{"nctId":"NCT03486314","phase":"PHASE1","title":"A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2018-08-13","conditions":"Advanced Solid Neoplasm","enrollment":20},{"nctId":"NCT04493931","phase":"PHASE1","title":"Drug-drug Interaction Study of Gepotidacin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-14","conditions":"Infections, Bacterial","enrollment":64},{"nctId":"NCT04558216","phase":"PHASE1","title":"Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants","status":"WITHDRAWN","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2020-09-30","conditions":"Healthy Participants","enrollment":""},{"nctId":"NCT04553406","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease","status":"TERMINATED","sponsor":"Spero Therapeutics","startDate":"2020-12-03","conditions":"Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease","enrollment":2},{"nctId":"NCT03709355","phase":"PHASE1","title":"Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-11-14","conditions":"HIV-1-infection","enrollment":56},{"nctId":"NCT01571414","phase":"PHASE1","title":"Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05","conditions":"Tuberculosis","enrollment":52},{"nctId":"NCT00802802","phase":"PHASE1","title":"Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-02-10","conditions":"HIV Infections, Tuberculosis","enrollment":67},{"nctId":"NCT04565574","phase":"PHASE1","title":"A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2020-10-16","conditions":"Healthy Participants","enrollment":42},{"nctId":"NCT04439578","phase":"PHASE1","title":"Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-06-23","conditions":"Healthy Subjects","enrollment":18},{"nctId":"NCT05069870","phase":"PHASE1","title":"A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-06-07","conditions":"Healthy Subjects","enrollment":42},{"nctId":"NCT04029584","phase":"PHASE4","title":"Drug-Drug Interaction Between Rifampin and Fluvastatin","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-04-25","conditions":"Drug-drug Interaction","enrollment":10},{"nctId":"NCT03384121","phase":"PHASE1","title":"The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH","status":"UNKNOWN","sponsor":"The Hospital for Sick Children","startDate":"2018-02-22","conditions":"Idiopathic Infantile Hypercalcemia - Mild Form","enrollment":5},{"nctId":"NCT04584515","phase":"PHASE1","title":"IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Impact Therapeutics, Inc.","startDate":"2020-11-02","conditions":"Solid Tumor","enrollment":32},{"nctId":"NCT04843449","phase":"PHASE1","title":"Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2021-04-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT04843540","phase":"PHASE1","title":"Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Concert Pharmaceuticals","startDate":"2021-05-19","conditions":"Healthy Volunteers","enrollment":22},{"nctId":"NCT03296800","phase":"PHASE1","title":"Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-09-27","conditions":"Type 2 Diabetes Mellitus","enrollment":48},{"nctId":"NCT01561963","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-02-01","conditions":"Healthy Subjects","enrollment":21},{"nctId":"NCT04914936","phase":"PHASE1","title":"A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-09-21","conditions":"Healthy Participants","enrollment":72},{"nctId":"NCT01960257","phase":"PHASE4","title":"Wirelessly Observed Therapy in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2013-10-25","conditions":"Tuberculosis","enrollment":92},{"nctId":"NCT04135833","phase":"PHASE1","title":"A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711","status":"COMPLETED","sponsor":"Beta Pharma, Inc.","startDate":"2019-12-12","conditions":"NSCLC","enrollment":31},{"nctId":"NCT04808648","phase":"PHASE1","title":"The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028","status":"UNKNOWN","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2021-04-06","conditions":"Healthy Male Volunteers","enrollment":40},{"nctId":"NCT01947777","phase":"PHASE1","title":"Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145","status":"COMPLETED","sponsor":"SecuraBio","startDate":"2013-10","conditions":"Healthy","enrollment":14},{"nctId":"NCT04410094","phase":"PHASE1","title":"A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-14","conditions":"Healthy","enrollment":32},{"nctId":"NCT02178592","phase":"PHASE3","title":"Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-01-23","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":113},{"nctId":"NCT04121078","phase":"PHASE1","title":"A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2019-10-15","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT02706535","phase":"PHASE1","title":"A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05-05","conditions":"Drug Interactions, Neoplasms","enrollment":29},{"nctId":"NCT04577885","phase":"PHASE1","title":"A Rifampin Effect Study of SHR2554 on Healthy Chinese Adult Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-05-28","conditions":"Healthy","enrollment":18},{"nctId":"NCT04494659","phase":"PHASE1","title":"A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on Famitinib","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-20","conditions":"Healthy Adult Subjects","enrollment":21},{"nctId":"NCT04266509","phase":"PHASE1","title":"Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-25","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT03928327","phase":"PHASE1","title":"A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2019-05-02","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT04171739","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim","status":"COMPLETED","sponsor":"F2G Biotech GmbH","startDate":"2019-11-18","conditions":"Healthy","enrollment":24},{"nctId":"NCT03334734","phase":"PHASE2","title":"Phase 2a Study of PBTZ169","status":"TERMINATED","sponsor":"Nearmedic Plus LLC","startDate":"2016-12-16","conditions":"Tuberculosis","enrollment":16},{"nctId":"NCT04142762","phase":"PHASE1","title":"A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2019-10-18","conditions":"Chronic Hepatitis B","enrollment":80},{"nctId":"NCT03311841","phase":"PHASE1","title":"Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-03-01","conditions":"Renal Insufficiency","enrollment":32},{"nctId":"NCT04150367","phase":"","title":"Efficacy and Safety of Intravenous Treatment of Tuberculosis","status":"TERMINATED","sponsor":"Yuria-Pharm","startDate":"2017-03-03","conditions":"Tuberculosis, Pulmonary","enrollment":166},{"nctId":"NCT03991312","phase":"PHASE1","title":"Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2019-06-20","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT02216331","phase":"PHASE1","title":"PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2010-03","conditions":"Tuberculosis","enrollment":32},{"nctId":"NCT03758469","phase":"PHASE1","title":"A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules","status":"COMPLETED","sponsor":"Sichuan Haisco Pharmaceutical Group Co., Ltd","startDate":"2018-12-14","conditions":"Anesthesia, Sedation","enrollment":16},{"nctId":"NCT01700790","phase":"PHASE4","title":"Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin","status":"TERMINATED","sponsor":"University of Miami","startDate":"2016-02","conditions":"AIDS, Tuberculosis","enrollment":9},{"nctId":"NCT03278483","phase":"PHASE4","title":"Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL)","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2019-02-28","conditions":"Diabetes Mellitus, Tuberculin (Skin Test) Positive","enrollment":396},{"nctId":"NCT01844583","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2013-06-25","conditions":"Solid Tumors, Lymphoma","enrollment":55},{"nctId":"NCT00108862","phase":"PHASE4","title":"Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2006-08","conditions":"HIV Infection, Tuberculosis","enrollment":809},{"nctId":"NCT03048110","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-02-15","conditions":"Biological Availability","enrollment":15},{"nctId":"NCT03478033","phase":"NA","title":"Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2018-04-15","conditions":"Tuberculosis, Pulmonary, AIDS","enrollment":230},{"nctId":"NCT00439166","phase":"PHASE3","title":"Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2007-02","conditions":"Alzheimer's Disease","enrollment":100},{"nctId":"NCT03258372","phase":"PHASE1","title":"Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2017-08-16","conditions":"Healthy","enrollment":48},{"nctId":"NCT03326050","phase":"EARLY_PHASE1","title":"Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-02","conditions":"Rhinoscleroma","enrollment":60},{"nctId":"NCT03186482","phase":"PHASE1","title":"RIFT: Effect of Rifampicin on Plasma PK of FTC, TAF and Intracellular TFV-DP & FTC-TP","status":"COMPLETED","sponsor":"St. Stephens Clinical Research","startDate":"2017-06-01","conditions":"HIV","enrollment":21},{"nctId":"NCT02409004","phase":"PHASE1","title":"Effects of Rifampin on the Pharmacokinetics of Ataluren","status":"COMPLETED","sponsor":"PTC Therapeutics","startDate":"2015-02","conditions":"Healthy","enrollment":15},{"nctId":"NCT01408914","phase":"PHASE2","title":"Trial of High-Dose Rifampin in Patients With TB","status":"COMPLETED","sponsor":"Harvard University Faculty of Medicine","startDate":"2013-09","conditions":"Tuberculosis","enrollment":180},{"nctId":"NCT01454076","phase":"PHASE1","title":"Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2011-11-10","conditions":"Nonhematologic Malignancies, Lymphoma","enrollment":112},{"nctId":"NCT00405080","phase":"PHASE1","title":"A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11-11","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":12},{"nctId":"NCT02953847","phase":"PHASE1","title":"The Bioavailability of Rifampicin in (FDCs) Widely Used in South Africa to Treat Drug-susceptible (TB)","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2016-11","conditions":"Tuberculosis","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rifampicin","rifampin"],"phase":"marketed","status":"active","brandName":"Rifampicin Capsules","genericName":"Rifampicin Capsules","companyName":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","companyId":"suzhou-zelgen-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis. Used for Tuberculosis (pulmonary and extrapulmonary), Leprosy, Atypical mycobacterial infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}